| 产品描述 | T-1095 is an inhibitor of sodium-glucose cotransporter 1 (SGLT1) and SGLT2 (IC50s = 22.8 and 2.3 µM, respectively).1Dietary administration of T-1095 (0.01% w/w) reduces blood glucose and HbA1c levels in a rat model of diabetes induced by streptozotocin . It suppresses the development of hyperglycemia and hypertriglyceridemia and reduces HbA1c levels in the KKAγ mouse model of type 2 diabetes. T-1095 exacerbates post-infarction cardiac dysfunction in a rat model of left anterior descending coronary artery ligation-induced myocardial infarction.2 1.Oku, A., Ueta, K., Ishihara, T., et al.T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetesDiabetes48(9)1794-1800(1999)
2.Bruno, J.G., Herman, T.S., Cano, V.L., et al.Selective cytotoxicity of 3-amino-L-tyrosine correlates with peroxidase activityIn Vitro Cell. Dev. Biol. Anim.35(7)376-382(1999) |
